Who is sponsoring NCT04898621?

NCT04898621 is sponsored by Shanghai Zhongshan Hospital.

What condition does NCT04898621 study?

NCT04898621 studies Hepatic Steatosis, Dietary Fructose Exposure.

What drugs are being tested in NCT04898621?

Interventions: 75g fructose solution, 150g fructose solution.

What is the status of NCT04898621?

NCT04898621 is currently COMPLETED.

Last reviewed 2023-06-07 · How we verify

Dietary Fructose on Microbiota and Hepatosteatosis

NCT04898621 NA COMPLETED

The consumption of sugar-sweetened beverages (SSB) has increased steadily over the past decades, resulting in the dramatic increase of fructose intake as it is one of the main ingredients of artificial sweeteners. Recently, large epidemiological studies have documented the association between a high-fructose-diet and hepatic steatosis, and other metabolic disorders. So it is interesting for scientists to explore the underlying mechanism. This study aims to investigate the effect of dietary fructose and gut microbiota and the hepatosteatosis in healthy men. Serum and fecal metabolomics will be investigated.

Details

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	COMPLETED
Enrolment	58
Start date	Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Dec 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Hepatic Steatosis
Dietary Fructose Exposure

Interventions

75g fructose solution
150g fructose solution

Countries

China